Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal associations of cardiovascular health and vascular events with incident dementia.

Stroke and vascular neurology·2023
Same author

Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy.

Journal of Parkinson's disease·2023
Same author

Inflammation and Brain Structure in Alzheimer's Disease and Other Neurodegenerative Disorders: a Mendelian Randomization Study.

Molecular neurobiology·2023
Same author

Association of biological age with health outcomes and its modifiable factors.

Aging cell·2023
Same author

The causal role of circulating amino acids on neurodegenerative disorders: A two-sample Mendelian randomization study.

Journal of neurochemistry·2023
Same author

TMEM106B aggregation in neurodegenerative diseases: linking genetics to function.

Molecular neurodegeneration·2023
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Mei Cui1,2, Yu-Yuan Huang3, Yiren Fan2

  • 1MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

This Phase III trial shows 18F-florzolotau (18F-APN-1607) PET imaging is a sensitive and specific tool for diagnosing Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD. The tracer is safe and correlates with disease severity.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Radiochemistry
  • Medical Imaging

Background:

  • Alzheimer's disease (AD) is characterized by beta-amyloid (Aβ) and tau pathology.
  • 18F-florzolotau (18F-APN-1607) enables high-contrast tau imaging in AD and non-AD conditions.
  • Previous trials assessed 18F-APN-1607's pharmacokinetics, safety, and diagnostic efficacy.

Purpose of the Study:

  • To demonstrate the sensitivity, specificity, and safety of 18F-APN-1607 for diagnosing MCI due to AD and AD dementia.
  • To highlight the correlation between tau pathology staging and clinical severity in AD patients.

Main Methods:

  • A multicenter, Phase III clinical trial involving 30 healthy volunteers, 100 MCI due to AD, and 100 AD dementia patients.
  • Utilized Subjective Reading Analysis and SUVR-Based Reading Analysis to determine sensitivity and specificity for tau deposition.
  • Assessed safety and tolerability, and explored correlations between 18F-APN-1607 SUVR, Braak staging, and clinical severity.

Main Results:

  • High diagnostic accuracy for 18F-APN-1607 PET in differentiating AD from healthy volunteers (AUC 0.982 in MTL, 0.979 in neocortex).
  • Good accuracy in distinguishing MCI from healthy volunteers (AUC 0.842 in MTL, 0.869 in neocortex).
  • No serious adverse events reported; observed distinct tau accumulation patterns correlating with Braak stages and clinical severity (CDR, MMSE, ADAS-cog scores).

Conclusions:

  • 18F-APN-1607 demonstrates good specificity and sensitivity for diagnosing AD.
  • The tracer is safe and reliable for AD diagnosis.
  • 18F-APN-1607 may serve as a biomarker for tracking AD progression and cognitive decline.